The US Food and Drug Administration (FDA) has accepted an Investigational New Drug (IND) application for Antag Therapeutics’ lead molecule AT-7687 for obesity. The company has announced plans to initiate a Phase I clinical trial, which will evaluate the safety, tolerability, and pharmacokinetics of AT-7687 in both healthy lean and healthy obese subjects. AT-7687 is […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!
